The Filing Desk

CorMedix vs Evolus

CorMedix CRMD · Evolus EOLS · Pharmaceuticals

CorMedix reported revenue of $312 million in fiscal 2025, about the same as Evolus' $297 million in fiscal 2025. CorMedix's revenue grew 617.0% in its latest year, and Evolus' grew 11.6%. CorMedix had an operating margin of 48.2%, against -11.0% at Evolus. Free cash flow was $173 million at CorMedix and −$46 million at Evolus.

Side by side

CorMedixEvolus
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$312M$297M
Revenue growth617.0%11.6%
Revenue growth a year, last 5 years335.1%39.4%
Gross margin88.5%66.3%
Operating margin48.2%−11.0%
Net margin52.3%−17.4%
Free cash flow$173M−$46M
Free cash flow margin55.4%−15.4%
Return on capital—−47.2%
Net debt to EBITDA−0.9x—
Dividends and buybacks$0M$0M
Change in diluted share count36.4%4.0%
Last close$4.66$6.96
P/E at the last close7.8×—
Insider trades, last 12 months——
Piotroski F-score—2 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CorMedixEvolus
Operating margin
Percent of revenue
CorMedixEvolus
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CorMedixEvolus

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CorMedix and Evolus pages.